Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Pharmaceuticals Inc.

www.auriniapharma.com

Latest From Aurinia Pharmaceuticals Inc.

Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?

Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II study.

Renal Immune Disorders

Takeda Offloads Xiidra As Expected, For $3.4bn Upfront To Novartis

As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.

Ophthalmic Deals

TopiVert Seeks Slot In Dry Eye Disease

The London-based group has begun a Phase IIb/III study evaluating TOP1630 which has a safety and tolerability profile that could prove superior to current treatments such as Allergan's market leader Restasis.

Ophthalmic Clinical Trials

Aurinia’s Voclosporin Misses Superior Tolerability Vs. Restasis, But Pushes On In Dry Eye

Aurinia's voclosporin missed the primary endpoint of superior tolerability compared to Restasis, but hit objective secondary efficacy endpoints that that may better position it for approval in dry eye.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Renal System
  • Alias(es)
  • Isotechnika Pharma Inc.
  • Isotechnika Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Aurinia Pharmaceuticals Inc.
  • Senior Management
  • Peter Greanleaf, CEO
    Dennis Bourgeault, CFO
    Neil Solomons, MD, CMO
    Michael Martin, COO
  • Contact Info
  • Aurinia Pharmaceuticals Inc.
    Phone: (250) 708-4272
    1203-4464 Markham St.
    Victoria, V8Z 7X8
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register